Chronic Spontaneous Urticaria Market is segmented By Treatment (H1-antihistamines, H2 antihistamines, Monoclonal Antibodies, Corticosteroids, Leukotriene Receptor Antagon ....
Market Size in USD
CAGR10.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 10.7% |
Market Concentration | Medium |
Major Players | Roche, Novartis, Sanofi/Regeneron, AstraZeneca, Amgen |
The chronic spontaneous urticaria market is estimated to be valued at USD 2.4 Bn in 2024 and is expected to reach USD 4.88 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031. The increasing prevalence of chronic spontaneous urticaria and growing awareness about its treatment options are contributing to the growth of this market.